pioglitazone has been researched along with Ventricular Dysfunction, Left in 12 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Ventricular Dysfunction, Left: A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Because proinflammatory cytokines play a critical role in left ventricular (LV) remodeling after myocardial infarction (MI), we examined the effects of pioglitazone treatment in an experimental model of chronic heart failure." | 7.71 | Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. ( Egashira, K; Hayashidani, S; Ikeuchi, M; Ishibashi, M; Kubota, T; Shiomi, T; Suematsu, N; Takeshita, A; Tsutsui, H; Wen, J, 2002) |
| "In T2DM patients, pioglitazone was associated with improvement in some measures of left ventricular diastolic function, myocardial glucose uptake, and whole-body insulin sensitivity." | 5.14 | Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. ( Bax, JJ; de Jong, HW; de Roos, A; Diamant, M; Heine, RJ; Kamp, O; Lamb, HJ; Lammertsma, AA; Lubberink, M; Paulus, WJ; Rijzewijk, LJ; Romijn, JA; Smit, JW; van der Meer, RW, 2009) |
| "In asymptomatic DM2 patients with LVDD, the addition of pioglitazone to oral conventional treatment for 6 months does not induce any adverse or favorable changes in LV diastolic or systolic function despite improvements in glycaemic control, insulin sensitivity, lipid profile, and blood pressure." | 5.14 | Lack of effects of pioglitazone on cardiac function in patients with type 2 diabetes and evidence of left ventricular diastolic dysfunction: a tissue doppler imaging study. ( Kanioglou, C; Katsouras, CS; Kazakos, N; Liveris, K; Makriyiannis, D; Michalis, LK; Naka, KK; Papamichael, ND; Papathanassiou, K; Pappas, K; Tsatsoulis, A, 2010) |
| " Therefore, we examined the effect of pioglitazone, a PPARgamma agonist, on chronic left ventricular remodeling after experimental myocardial infarction (MI) in mice." | 3.72 | Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction. ( Bauersachs, J; Bayer, B; Ertl, G; Frantz, S; Galuppo, P; Hu, K; Schmidt, I; Strotmann, J; Widder, J; Witzel, CC, 2004) |
| " Because proinflammatory cytokines play a critical role in left ventricular (LV) remodeling after myocardial infarction (MI), we examined the effects of pioglitazone treatment in an experimental model of chronic heart failure." | 3.71 | Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. ( Egashira, K; Hayashidani, S; Ikeuchi, M; Ishibashi, M; Kubota, T; Shiomi, T; Suematsu, N; Takeshita, A; Tsutsui, H; Wen, J, 2002) |
| "Pioglitazone treatment in type 2 diabetes mellitus produced significant improvements in glycaemic control, plasma lipids, blood pressure and inflammation." | 1.36 | Pioglitazone improves ventricular diastolic function in patients with diabetes mellitus: a tissue Doppler study. ( Alemdar, R; Aydin, M; Basar, C; Caglar, O; Ordu, S; Ozhan, H; Yalcin, S; Yazici, M, 2010) |
| "Pioglitazone was mixed in rat chow fed to the diabetic treated group (0." | 1.31 | Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat. ( Kohno, M; Miyatake, A; Mizushige, K; Murakami, K; Noma, T; Ohmori, K; Tsuji, T, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Furihata, T | 1 |
| Maekawa, S | 1 |
| Takada, S | 1 |
| Kakutani, N | 1 |
| Nambu, H | 1 |
| Shirakawa, R | 1 |
| Yokota, T | 1 |
| Kinugawa, S | 1 |
| Kamimura, D | 1 |
| Uchino, K | 1 |
| Ishigami, T | 1 |
| Hall, ME | 1 |
| Umemura, S | 1 |
| Joubert, M | 1 |
| Jagu, B | 1 |
| Montaigne, D | 1 |
| Marechal, X | 1 |
| Tesse, A | 1 |
| Ayer, A | 1 |
| Dollet, L | 1 |
| Le May, C | 1 |
| Toumaniantz, G | 1 |
| Manrique, A | 1 |
| Charpentier, F | 1 |
| Staels, B | 1 |
| Magré, J | 1 |
| Cariou, B | 1 |
| Prieur, X | 1 |
| van der Meer, RW | 1 |
| Rijzewijk, LJ | 1 |
| de Jong, HW | 1 |
| Lamb, HJ | 1 |
| Lubberink, M | 1 |
| Romijn, JA | 1 |
| Bax, JJ | 1 |
| de Roos, A | 1 |
| Kamp, O | 1 |
| Paulus, WJ | 1 |
| Heine, RJ | 1 |
| Lammertsma, AA | 1 |
| Smit, JW | 1 |
| Diamant, M | 1 |
| Gropler, RJ | 1 |
| Ordu, S | 1 |
| Ozhan, H | 1 |
| Alemdar, R | 1 |
| Aydin, M | 1 |
| Basar, C | 1 |
| Caglar, O | 1 |
| Yazici, M | 1 |
| Yalcin, S | 1 |
| Naka, KK | 1 |
| Pappas, K | 1 |
| Papathanassiou, K | 1 |
| Papamichael, ND | 1 |
| Kazakos, N | 1 |
| Kanioglou, C | 1 |
| Makriyiannis, D | 1 |
| Katsouras, CS | 1 |
| Liveris, K | 1 |
| Tsatsoulis, A | 1 |
| Michalis, LK | 1 |
| Tian, YQ | 1 |
| Li, SS | 1 |
| Su, XD | 1 |
| Zhang, GZ | 1 |
| Zhao, JJ | 1 |
| Li, GW | 1 |
| Wang, L | 1 |
| Shiomi, T | 1 |
| Tsutsui, H | 1 |
| Hayashidani, S | 1 |
| Suematsu, N | 1 |
| Ikeuchi, M | 1 |
| Wen, J | 1 |
| Ishibashi, M | 1 |
| Kubota, T | 1 |
| Egashira, K | 1 |
| Takeshita, A | 1 |
| Frantz, S | 1 |
| Hu, K | 1 |
| Widder, J | 1 |
| Bayer, B | 1 |
| Witzel, CC | 1 |
| Schmidt, I | 1 |
| Galuppo, P | 1 |
| Strotmann, J | 1 |
| Ertl, G | 1 |
| Bauersachs, J | 1 |
| Rodriguez, WE | 1 |
| Joshua, IG | 1 |
| Falcone, JC | 1 |
| Tyagi, SC | 1 |
| Tsuji, T | 1 |
| Mizushige, K | 1 |
| Noma, T | 1 |
| Murakami, K | 1 |
| Ohmori, K | 1 |
| Miyatake, A | 1 |
| Kohno, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus[NCT01761318] | Phase 4 | 50 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for pioglitazone and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus.
Topics: Adenosine Triphosphate; Aged; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combi | 2009 |
Lack of effects of pioglitazone on cardiac function in patients with type 2 diabetes and evidence of left ventricular diastolic dysfunction: a tissue doppler imaging study.
Topics: Aged; Blood Pressure; Diabetes Mellitus, Type 2; Diastole; Echocardiography, Doppler; Heart Function | 2010 |
10 other studies available for pioglitazone and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Premedication with pioglitazone prevents doxorubicin-induced left ventricular dysfunction in mice.
Topics: Animals; Antibiotics, Antineoplastic; Cardiotonic Agents; Doxorubicin; Male; Mice, Inbred C57BL; Myo | 2021 |
Activation of Peroxisome Proliferator-activated Receptor γ Prevents Development of Heart Failure With Preserved Ejection Fraction; Inhibition of Wnt-β-catenin Signaling as a Possible Mechanism.
Topics: Animals; beta Catenin; Collagen Type I; Disease Models, Animal; Disease Progression; Fibrosis; Heart | 2016 |
The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Cardiomyopathy, Hypertrophic; Diabetes Mellitus, Type | 2017 |
Lost in translation: modulation of the metabolic-functional relation in the diabetic human heart.
Topics: Animals; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fatty A | 2009 |
Pioglitazone improves ventricular diastolic function in patients with diabetes mellitus: a tissue Doppler study.
Topics: Blood Flow Velocity; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Dias | 2010 |
Effects of pioglitazone on high-fat-diet-induced ventricular remodeling and dysfunction in rats.
Topics: Animals; Blood Pressure; Diet, High-Fat; Echocardiography; Fatty Acids, Nonesterified; Hypertrophy, | 2012 |
Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction.
Topics: Administration, Oral; Animals; Aspartate Aminotransferases; Blood Glucose; Cytokines; Disease Models | 2002 |
Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction.
Topics: Animals; Aorta; Blood Glucose; Body Weight; Chronic Disease; Collagen; Coronary Vessels; Cytokines; | 2004 |
Pioglitazone prevents cardiac remodeling in high-fat, high-calorie-induced Type 2 diabetes mellitus.
Topics: Animals; Diabetes Mellitus, Type 2; Dietary Fats; Dose-Response Relationship, Drug; Energy Intake; H | 2006 |
Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat.
Topics: Animals; Blood Glucose; Collagen; Diabetes Mellitus, Type 2; Diastole; Echocardiography, Doppler; He | 2001 |